Citations

Showing 10 of 108094 citations.

Accelerated LVAD Pump Thrombosis in COVID-19 Patient: Case report and Mini review
Wadiwala, Ishaq , Garg, Pankaj , Alomari, Mohammad , Elawady, Mohamed , Alamouti-fard, Emad, Raavi, Lekhya , Mateen, Nargis, Khan, Fazal Wahab , Hussain, Md Walid Akram , Jacob, Samuel , Wadiwala, Ishaq J , Garg, Pankaj , Pham, Si M.

Mayo Clinic

No container title available | September 30, 2022 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.22541/au.166453983.32235498/v1 Get It

Coronavirus (COVID-19) infection exposes patients with heart failure to a higher risk of morbidity and mortality. In LVAD patients, one of the key problems that can lead to life-threatening low-flow or pump malfunction due to thrombus development in the inflow cannula, device body, or outflow graft, implicating hemodynamic instability, hemolysis, renal or hepatic failure, or cerebral or peripheral thromboembolism. [Endothelial protein C receptor and thrombomodulin levels are elevated along with procoagulants such as factor VIII, P-selectin, and von Willebrand factor and downregulated along with thrombomodulin as a result of the cytokine storm released by endothelial and immune cells. In general ,](#ref-0013) LVAD thrombosis has been found to occur in 2–13% of adult patients who use current continuous-flow devices. However, LVAD thrombosis due to COVID-19 is underreported and a few cases presented. We present a case of accelerated LVAD outflow thrombosis in the setting of COVID-19 infection with multiorgan failure.
Restoration of hamstring function following sciatic nerve resection at the greater sciatic foramen with reconstruction involving acellular nerve allograft and vascularized sural nerve autograft: A case report
Sarcon, Aida K. , Li, Neill Y. , Houdek, Matthew T. , Moran, Steven L. , Houdek, Matthew T

Mayo Clinic

Microsurgery | September 30, 2022 | Volume: 42 | Issue: 8 | Pages: 824-828

10.1002/micr.30970 | PMID 36177748 Get It

AbstractSegmental loss of the sciatic nerve secondary to oncologic resection or trauma is detrimental to hamstring and leg function. The diameter of this nerve and the length of its axons spanning the lower extremity create significant challenges in reconstruction and optimizing return of sensory or motor function. The purpose of this report is to describe outcomes of a free vascularized sural nerve graft to preserve hamstring function in a large proximal sciatic nerve defect beginning at the greater sciatic foramen. A 44‐year‐old female underwent neoadjuvant chemotherapy and radiation for treatment of a left sciatic nerve synovial cell sarcoma. The patient underwent R0 resection of the proximal left sciatic nerve resulting in a 15 cm defect. An ipsilateral vascularized sural nerve graft was used to reconstruct the medial aspect of the sciatic nerve, prioritizing the tibial division, in an effort to restore hamstring function and plantar sensation. A 5 cm allograft nerve was added to the cutaneous branches of the sural nerve graft to better span the large defect and reconstruct the lateral aspect of the nerve. The patient's postoperative course was uneventful. At 1‐year follow‐up, the patient showed MRC grade 4/5 strength with knee flexion and steady gait pattern with a left ankle‐foot orthosis. Outcomes support the use of a single vascularized nerve graft alongside acellular nerve allograft to restore motor function in large diameter and large defect mixed nerve injuries.
Early ACLR and Risk and Timing of Secondary Meniscal Injury Compared With Delayed ACLR or Nonoperative Treatment: A Time-to-Event Analysis Using Machine Learning
Lu, Yining , Jurgensmeier, Kevin , Till, Sara E., Reinholz, Anna K., Saris, Daniël B.F. , Krych, Aaron J. , Reinholz, Anna, Krych, Aaron J , Lu, Yining , Jurgensmeier, Kevin , Camp, Christopher L.

Mayo Clinic

The American Journal of Sports Medicine | September 30, 2022 | Volume: 50 | Issue: 13 | Pages: 3544-3556

10.1177/03635465221124258 | PMID 36178166 Get It

Background: Surgical and nonoperative management of anterior cruciate ligament (ACL) injuries seek to mitigate the risk of knee instability and secondary meniscal injury. However, the associated risk and timing of secondary meniscal tears have not been completely elucidated. Purpose: To compare risk and timing of secondary meniscal injury between patients receiving nonoperative management, delayed ACL reconstruction (ACLR), and early ACLR using a machine learning survival analysis. Study Design: Cohort study; Level of evidence, 3. Methods: A geographic database was used to identify and review records of patients with a diagnosis of ACL rupture between 1990 and 2016 with minimum 2-year follow-up. Patients undergoing ACLR were matched 1:1 with nonoperatively treated controls. Rate and time to secondary meniscal tear were compared using random survival forest algorithms; independent models were developed and internally validated for predicting injury-free duration in both cohorts. Performance was measured using out-of-bag c-statistic, calibration, and Brier score. Model interpretability was enhanced using global variable importance and partial dependence curves. Results: The study included 1369 patients who underwent ACLR and 294 patients who had nonoperative treatment. After matching, no significant differences in rates of secondary meniscal tear were found ( P = .09); subgroup analysis revealed the shortest periods of meniscal survival in patients undergoing delayed ACLR. The random survival forest algorithm achieved excellent predictive performance for the ACLR cohort, with an out-of-bag c-statistic of 0.80 and a Brier score of 0.11. Significant variables for risk of meniscal tear for the ACLR cohort included time to return to sports or activity ≤350 days, time to surgery ≥50 days, age at injury ≤40 years, and high-impact or rotational landing sports, whereas those in the nonoperative cohort model included time to RTS ≤200 days, visual analog scale pain score >3 at consultation, hypermobility, and noncontact sports. Conclusion: Delayed ACLR demonstrated the greatest long-term risk of meniscal injury compared with nonoperative treatment or early ACLR. Risk factors for decreased meniscal survival after ACLR included increased time to surgery, shorter time to return to sports or activity, older age at injury, and involvement in high-impact or rotational landing sports. Pending careful external validation, these models may be deployed in the clinical space to provide real-time insights and enhance decision making.
Reduced calf pump function and proximal deep vein incompetence are predictors for ipsilateral deep vein thrombosis
Houghton, Damon E. , Ashrani, Aneel A. , Liedl, David , Mehta, Ramila A. , Hodge, David O. , Rooke, Thom W. , Wennberg, Paul W. , McBane, Robert D. , Ashrani, Aneel, Rooke, Thom, Wennberg, Paul, McBane, Robert , Houghton, Damon E , Wysokiński, Waldemar E.

Mayo Clinic

Vascular Medicine | September 30, 2022 | Volume: 28 | Issue: 1 | Pages: 57-58

10.1177/1358863x221124996 | PMID 36178146 Get It

Revision total knee arthroplasty for flexion instability
Hannon, Charles P. , Kruckeberg, Bradley M. , Pagnano, Mark W. , Berry, Daniel J. , Hanssen, Arlen D. , Abdel, Matthew P. , Abdel, Matthew P , Berry, Daniel J , Hannon, Charles P

Mayo Clinic

The Bone & Joint Journal | September 30, 2022 | Volume: 104-B | Issue: 10 | Pages: 1126-1131

10.1302/0301-620x.104b10.bjj-2022-0358.r1 | PMID 36177638 Get It

Aims We have previously reported the mid-term outcomes of revision total knee arthroplasty (TKA) for flexion instability. At a mean of four years, there were no re-revisions for instability. The aim of this study was to report the implant survivorship and clinical and radiological outcomes of the same cohort of of patients at a mean follow-up of ten years. Methods The original publication included 60 revision TKAs in 60 patients which were undertaken between 2000 and 2010. The mean age of the patients at the time of revision TKA was 65 years, and 33 (55%) were female. Since that time, 21 patients died, leaving 39 patients (65%) available for analysis. The cumulative incidence of any re-revision with death as a competing risk was calculated. Knee Society Scores (KSSs) were also recorded, and updated radiographs were reviewed. Results The cumulative incidence of any re-revision was 13% at a mean of ten years. At the most recent-follow-up, eight TKAs had been re-revised: three for recurrent flexion instability (two fully revised to varus-valgus constrained implants (VVCs), and one posterior-stabilized (PS) implant converted to VVC, one for global instability (PS to VVC), two for aseptic loosening of the femoral component, and two for periprosthetic joint infection). The ten-year cumulative incidence of any re-revision for instability was 7%. The median KSS improved significantly from 45 (interquartile range (IQR) 40 to 50) preoperatively to 70 (IQR 45 to 80) at a mean follow-up of ten years (p = 0.031). Radiologically, two patients, who had not undergone revision, had evidence of loosening (one tibial and one patellar). The remaining components were well fixed. Conclusion We found fair functional outcomes and implant survivorship at a mean of ten years after revision TKA for flexion instability with a PS implant. Recurrent instability and aseptic loosening were the most common indications for re-revision. Components with increased constraint, such as a VVC or hinged, should be used in these patients in order to reduce the risk of recurrent instability. Cite this article: Bone Joint J 2022;104-B(10):1126–1131.
Supporting International Medical Graduates in Rheumatology: A Call to Action
Fernandez‐Ruiz, Ruth , Duarte‐García, Alí , Rolle, Noelle A. , Sattui, Sebastian E. , Saygın, Didem , Dowell, Sharon , Alexander, Swetha Ann , Kumar, Bharat , Danila, Maria I. , Singh, Namrata , Duarte-García, Alí , Sattui, Sebastian E

Mayo Clinic

Arthritis & Rheumatology | September 30, 2022 | Volume: 75 | Issue: 2 | Pages: 145-148

10.1002/art.42373 | PMID 36177492 Get It

Colectomy Complicated by High-Output Ileostomy Managed in a Virtual Hybrid Hospital-at-Home Program
Paulson, Margaret R. , Maita, Karla C. , Ávila, Francisco R. , Torres‐Guzman, Ricardo A. , Garcia, John P. , Eldaly, Abdullah S. , Forte, Antonio J. , Maniaci, Michael J. , Maita, Karla , Eldaly, Abdullah , Forte, Antonio Jorge , Torres, Ricardo A , Maniaci, Michael J , Avila, Francisco R , Garcia, John P , Paulson, Margaret R

Mayo Clinic

Case Reports in Surgery | September 30, 2022 | Volume: 2022 | Issue: No issue available | Pages: 1-6

10.1155/2022/3177934 | PMID 36213589 Get It

Chronically ill patients with superimposed acute illness requiring hospitalization are more likely to develop an extended length of stay, hospital-acquired infections, and adverse events throughout their hospitalization. An excellent alternative to managing this population of patients in the traditional bricks-and-mortal (BAM) hospital is the hospital-at-home (HaH) model. The Advanced Care at Home (ACH) program is Mayo Clinic’s HaH model that provides acute and postacute care to high-acuity patients in their homes rather than in the traditional hospital and skilled nursing facility. We report a case of postoperative care through the ACH program of a patient suffering from short gut syndrome, high-output ileostomy, and severe protein-calorie malnutrition in the setting of previously diagnosed triple-negative invasive ductal carcinoma (IDC) of the right breast complicated by lung and brain metastasis. The patient had multiple complications that required repeated scare escalations directed by a multidisciplinary virtual care. Despite these complications, the ACH model of care was able to keep the patient in the home setting the majority of the time, limiting BAM hospital days, and eliminating the need to use the emergency department for acute escalation for 3 months. The patient was able to recover during this time period and proceed to successful take-down of the ileostomy. This case highlights the benefits of the ACH program by offering high-acuity hospital-level care to severely ill patients in the comfort of their homes. Highly qualified providers paired with curated technology in the home allowed for prompt identification of patient decompensation and timely initiation of treatment while avoiding institutionalization.
Nosocomial Infections in COVID-19 Patients Treated with Immunomodulators: A Narrative Review
Ramasamy, Chidambaram , Narayan, Gayatri , Mishra, Ajay Kumar , John, Kevin , Lal, Amos , Mishra, Ajay K , Lal, Amos , John, Kevin John , Ramasamy, Chidambaram

Mayo Clinic

Frontiers in Bioscience-Scholar | September 30, 2022 | Volume: 14 | Issue: 4 | Pages: No page available

10.31083/j.fbs1404026 | PMID 36575837 Get It

Nosocomial infections pose an imminent challenge to hospitalized Coronavirus disease-19 (COVID-19) patients due to complex interplay of dysregulated immune response combined with immunomodulator therapy. In the pre-pandemic era, immunomodulatory therapy has shown benefit in certain autoimmune conditions with untamed inflammatory response. Efforts to recapitulate these immunomodulatory effects in COVID-19 patients has gained impetus and were followed by NIH COVID-19 expert panel recommendations. The current NIH guideline recommends interleukin-6 inhibitors (tocilizumab and sarilumab) and Janus kinase inhibitors (baricitinib and tofacitinib). Several landmark research trials like COVAVTA, EMPACTA, REMDACTA, STOP-COVID and COV BARRIER have detailed the various effects associated with administration of immunomodulators. The historical evidence of increased infection among patients receiving immunomodulators for autoimmune conditions, raised concerns regarding administration of immunomodulators in COVID-19 patients. The aim of this review article is to provide a comprehensive update on the currently available literature surrounding this issue. We reviewed 40 studies out of which 37 investigated IL-6 inhibitors and 3 investigated JAK inhibitors. Among the studies reviewed, the reported rates of nosocomial infections among the COVID-19 patients treated with immunomodulators were similar to patients receiving standard of care for COVID-19. However, these studies were not powered to assess the side effect profile of these medications. Immunomodulators, by dampening the pyrogenic response and inflammatory markers may delay detection of infections among the patients. This underscores the importance of long-term surveillance which are necessary to discover the potential risks associated with these agents.
Early versus Late Discontinuation of Maintenance Therapy in Multiple Myeloma
Nunnelee, Jordan , Cottini, Francesca , Zhao, Qiuhong , Faisal, Muhammad Salman , Elder, Patrick , Rosko, Ashley , Bumma, Naresh , Khan, Abdullah , Umyarova, Elvira , Devarakonda, Srinivas , Benson, Don M. , Efebera, Yvonne A. , Sharma, Nidhi

Mayo Clinic

Journal of Clinical Medicine | September 29, 2022 | Volume: 11 | Issue: 19 | Pages: 5794

10.3390/jcm11195794 | PMID 36233663 Get It

Maintenance therapy after autologous stem cell transplant (ASCT) in multiple myeloma (MM) is the standard treatment and recommended to be continued until disease progression. However, in the real world, patients discontinue treatment due to various reasons. We sought to determine the effect of early versus late discontinuation on survival outcomes in MM patients who underwent ASCT at The Ohio State University. We retrospectively reviewed 340 patients who underwent ASCT from 2005 to 2016 and received maintenance therapy for at least six months without progression. We compared the outcomes of patients who received maintenance for three years or less (early group) to the patients who continued maintenance beyond three years (late group). Lenalidomide (89%) and bortezomib (10%) were the most common agents used for maintenance chemotherapy. In Kaplan–Meier analysis, patients in the late group had prolonged progression-free (PFS) (p < 0.001) and overall survival (OS) (p < 0.001). The 5-year estimated OS in late group was 96% vs. 79% in the early group and 5-year PFS was 80% in late group vs. 50% in the early group. The most common reasons for discontinuation of maintenance in early group were adverse events (55.9%) and patient preference (22.5%). For the late group, it was disease progression (23.9%) and adverse events (14.3%). Fifty-five percent of patients in the late group were still on maintenance treatment at the last follow-up. Continuation of maintenance therapy was thus associated with improved outcomes, while adverse events prevented most patients from continuing treatment.
Von Willebrand Factor Multimer Analysis and Classification: A Comprehensive Review and Updates
Seheult, Jansen N. , Pruthi, Rajiv K. , Seheult, Jansen, Seheult, Jansen N , Saadalla, Abdulrahman , Chen, Dong

Mayo Clinic

Seminars in Thrombosis and Hemostasis | September 29, 2022 | Volume: 49 | Issue: 06 | Pages: 580-591

10.1055/s-0042-1757183 | PMID 36174612 Get It

AbstractVon Willebrand factor (VWF) is a multimeric glycoprotein with essential roles in primary hemostasis. Patients with von Willebrand disease (VWD), due to quantitative and/or qualitative defects of VWF usually experience mucocutaneous bleeding. Based on the laboratory results of VWF antigen, various VWF activities, factor VIII activity, and VWF multimer patterns, VWD can be categorized as type 1, 2, and 3 VWD. VWF multimer analysis by either manual or semi-automated electrophoresis and immunoblotting is a critical part of the laboratory testing to differentiate type 1, type 2 VWD, and subtypes of type 1 or 2 VWD. The multimer distribution patterns can also help to understand the underlying molecular mechanism of VWF synthesis, multimerization, and clearance defects in VWD. This review will cover VWF synthesis, multimerization, secretion, VWF multimer analysis, and VWF multimer interpretation of various types and subtypes of VWD.